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ABSTRACT Recent genome-wide association studies (GWAS) have identiﬁed variants associated with high-
density lipoprotein cholesterol (HDL-C) located in or near the ANGPTL8 gene. Given the extensive sharing
of GWAS loci across populations, we hypothesized that at least one shared variant at this locus affects HDL-C.
The HDL-C–associated variants are coincident with expression quantitative trait loci for ANGPTL8 and DOCK6 in
subcutaneous adipose tissue; however, only ANGPTL8 expression levels are associated with HDL-C levels. We
identiﬁed a 400-bp promoter region of ANGPTL8 and enhancer regions within 5 kb that contribute to regulating
expression in liver and adipose. To identify variants functionally responsible for the HDL-C association, we
performed ﬁne-mapping analyses and selected 13 candidate variants that overlap putative regulatory regions
to test for allelic differences in regulatory function. Of these variants, rs12463177-G increased transcriptional
activity (1.5-fold, P = 0.004) and showed differential protein binding. Six additional variants (rs17699089,
rs200788077, rs56322906, rs3760782, rs737337, and rs3745683) showed evidence of allelic differences in
transcriptional activity and/or protein binding. Taken together, these data suggest a regulatory mechanism at
the ANGPTL8 HDL-C GWAS locus involving tissue-selective expression and at least one functional variant.
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To date, at least 157 loci have been associated with high-density
lipoprotein cholesterol (HDL-C) in genome-wide association studies
(GWAS) (Willer et al. 2013). Analyses of European, African American,
Mexican, Pima Indian, and East Asian participants have identiﬁed
four different lead variants associated with HDL-C located in or
near angiopoietin-like protein 8 (ANGPTL8) (Coram et al. 2013;
Weissglas-Volkov et al. 2013; Willer et al. 2013; Nair et al. 2016;
Spracklen et al. 2017). ANGPTL8 is a small protein of 198 amino
acids; the gene is located on chromosome 19 within intron 14 of
dedicator of cytokinesis 6 (DOCK6), and is transcribed in the opposite
direction of DOCK6. European GWAS meta-analyses identiﬁed
rs737337 (P = 4.6 · 10217, N = 185,000) (Teslovich et al. 2010; Willer
et al. 2013) as the lead variant associated with HDL-C; this variant was
also associated with total cholesterol (P = 4.1 · 1025) but not triglycer-
ides (P = 0.12) or low-density lipoprotein cholesterol (LDL-C, P = 0.26).
rs737337 is located 2.8 kb upstream of the ANGPTL8 transcription start
site (RefSeq NM_018687) and is a synonymous variant in exon 19 of
DOCK6 (Thr723, RefSeq NM_020812). In an African American
population, the lead variant rs12979813 was only associated with
HDL-C (P = 1.9 · 1029, N = 12,157) (Coram et al. 2013), which is
located 7.5 kb upstream of ANGPTL8 and in intron 22 of DOCK6.
In a joint analysis of Mexican and Pima Indian samples, the lead
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variant rs2278426 was associated with HDL-C (P = 3.4 · 1029, N =
4361) and total cholesterol (P = 5.0 · 1026) (Weissglas-Volkov et al.
2013; Hanson et al. 2016), which is a nonsynonymous variant in exon
2 of ANGPTL8 (Arg59Trp) that exhibits relatively high linkage disequi-
librium (LD) with the European lead rs737337 [r2 = 0.74, 1000G Ad-
mixed American (AMR)] and moderate LD with the African American
lead rs12979813 (r2 = 0.52 AMR). Finally, in recent lipid associations
in East Asian samples, lead variant rs3760782 was the strongest
HDL-C–associated variant (P = 8.8 · 10211) and another variant
in strong LD (rs1865063, r2= 0.95) is the lead variant for total cholesterol
(P = 1.5 · 10215) and LDL-C (P = 1.8 · 1028) (Spracklen et al. 2017).
rs3760782 is located 3.5 kb upstream of ANGPTL8 and in intron 20 of
DOCK6. Given the extensive sharing of GWAS loci across populations
(Visscher et al. 2012), we hypothesized that at least one shared variant at
the ANGPTL8 locus affects HDL-C in all of these populations.
ANGPTL8 is a recently deﬁned gene also called C19orf80, LOC55908,
refeeding-induced fat and liver (RIFL), TD26, hepatocellular carcinoma-
associated gene, lipasin, and betatrophin (Quagliarini et al. 2012; Ren
et al. 2012; Zhang 2012). Serum ANGPTL8 protein levels have been
associated with many metabolic phenotypes including type 1 and type
2 diabetes (Espes et al. 2014a,b; Fu et al. 2014b; Hu et al. 2014; Yamada
et al. 2015), obesity (Fu et al. 2014b; Lee et al. 2016), and nonalcoholic
fatty liver disease (Lee et al. 2016). The gene is mainly expressed in liver
and adipose tissues, despite being entirely contained within one intron of
the ubiquitously expressed DOCK6 (Quagliarini et al. 2012; GTEx Con-
sortium 2013). The precise mechanisms of action of ANGPTL8 remain
unclear. ANGPTL8 is secreted into the plasma and is involved in tri-
glyceride storage in adipose tissue; knockout mice gained less fat than
wild-type (Wang et al. 2013) mice and Angptl8 knockdown in 3T3L1
mouse adipocytes led to decreased triglyceride content (Ren et al. 2012).
ANGPTL8 expression is increased in response to stress, it upregulates
early growth response transcription factor and downregulates adipose
triglyceride lipase, suggesting a role in lipid homeostasis (Zhang et al.
2015). ANGPTL8 contains a lipoprotein lipase inhibitory motif and
inhibits LPL function when coexpressed with ANGPTL3 (Haller et al.
2017). Additionally, serumANGPTL8protein is inversely associatedwith
HDL-C levels (Yi et al. 2015) supporting a role of ANGPTL8 in HDL-C
metabolism.
DOCK6 is a member of the dedicator of cytokinesis family of atypical
guanine nucleotide exchange factors. DOCK6 is expressed in many tis-
sues, with highest levels of expression in the lungs, thyroid, and adipose
(GTEx Consortium 2013). DOCK6 functions as a guanine nucleotide
exchange factor for RAC1 and CDC42 and has roles in cytoskeletal
remodeling and neurite outgrowth (Miyamoto et al. 2007). Mutations
inDOCK6 can cause Adams-Oliver syndrome, an actin cytoskeletopathy
characterized by limb and skin defects (Shaheen et al. 2011).DOCK6 does
not have functions that obviously relate to HDL-C metabolism.
Two coding variants in ANGPTL8 have been proposed to affect
HDL-C levels. A rare ANGPTL8 nonsense variant, rs145464906
(MAF = 0.001 in.42,000 individuals of European ancestry) encoding
Gln121Ter, is associated with increased HDL-C (P = 5.1 · 10213) and
increased triglycerides (P = 0.003) in an exome array-based association
analysis (Peloso et al. 2014). Based on conditional analysis (Peloso et al.
2014) and LD (r2, 0.01), rs145464906 is independent of the reported
ANGPTL8 GWAS variants. The common Mexican and Pima Indian
lead variant, rs2278426 encoding Arg59Trp, has been proposed to in-
crease cleavage of ANGPTL3, leading to decreased LPL activity and
lower HDL-C (Hanson et al. 2016). Although coding variants have
been identiﬁed, the variants responsible for the common HDL-C as-
sociation signal at this locus remain unclear, and may include regula-
tory variants. While a simple mechanism involving a single variant
that alters transcription of a single gene is straightforward, multiple
variants and/or multiple genes may contribute to the functional
consequences of a GWAS signal (Corradin et al. 2014; He et al.
2015; Roman et al. 2015).
In this study, we describe an association between the HDL-C locus
variants and subcutaneous adipose level of ANGPTL8 RNA. We show
that a subset of HDL-C–associated variants overlap regions with strong
evidence of regulatory activity (Bernstein et al. 2010; Encode Project
Consortium 2012), and we use trans-ancestry ﬁne-mapping and func-
tional assays to identify variants exhibiting allelic differences in regu-
latory activity at the ANGPTL8 HDL-C GWAS locus.
MATERIALS AND METHODS
Study population and phenotypes
The METabolic Syndrome In Men (METSIM) study includes 10,197
men, aged from 45 to 73 yr, randomly selected from Kuopio, Eastern
Finland, and examined in 2005–2010 (Stancakova et al. 2009; Laakso
et al. 2017). The Ethics Committee of the University of Eastern Finland
in Kuopio and the Kuopio University Hospital approved the METSIM
study, and it was carried out in accordance with the Helsinki Declara-
tion. Triglyceride and lipoprotein characteristics were measured via
proton nuclear magnetic-resonance (NMR) or enzymatic assays in
10,079 METSIM participants (Inouye et al. 2010). DNA samples were
genotyped on the Illumina OmniExpress and HumanCoreExome ar-
rays, and additional genotypes were imputed using the GoT2D inte-
grated haplotypes reference panel as previously described (Fuchsberger
et al. 2016).
We also analyzed a set of 8421 self-identiﬁed African American
participants from the Women’s Health Initiative SNP Health Associa-
tion Resource (WHI-SHARe) study. Details of the study design, cohort
characteristics, written informed consent, and study approval by local
Human Subjects Committees have been described previously (Hays
et al. 2003). Participants who had consented to genetic research were
genotyped on the Affymetrix 6.0 array and additional genotypes were
imputed using the 1000 Genomes Project data as a reference panel, as
previously described (Reiner et al. 2012).
Association, conditional, and haplotype analysis
For METSIM, we performed a preliminary test for association between
19 million genetic variants and 72 lipid and lipoprotein subclasses
(Davis J.P., Huyghe J.R., Jackson A.U., Stringham H.M., Teslovich,
T.M., Welch R.P., Fuchsberger C., Locke A.E., Narisu N., Chines P.S.,
Kangas A.J., Soininen P., Ala-Korpela M., Kuusisto J., Collins F.S.,
Laakso M., Mohlke K.L., Boehnke M., unpublished data). To better
observe the relative differences between variants, we use the association
of variants with the concentration of phospholipids in medium HDL
because the association with this trait is stronger (P = 1.9 · 1027) than
with HDL-C (P = 7.7 · 1024). We assumed an additive mode of
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inheritance and accounted for cryptic relatedness between individuals
using the EMMAX mixed model (q.emmax test) implemented in
EPACTS (Kang et al. 2010). After accounting for age, BMI, smoking
status, and lipid-lowering medication status as covariates, trait value
residuals were inverse normal transformed. We carried out reciprocal
conditional analyses with candidate variants within the associated sig-
nal to evaluate the potential presence of a second association signal by
adjusting for speciﬁc genetic variants, including METSIM lead variant
rs737337 andWomen’s Health Initiative (WHI) lead variant rs4804154.
LD in locus plots was calculated from the METSIM imputed genotypes,
and all chromosome coordinates correspond to hg19.
For WHI, association analysis was performed under an additive
genetic model using linear regression adjusted for covariates. The
imputed allelic dosage at each variant was tested via MACH2QTL (Li
et al. 2010). Genome-wide African ancestry proportion, age, BMI, and
smoking history were included as covariates. Genome-wide African
ancestry proportion was derived from locus-speciﬁc ancestry, which
has a correlation of 0.99 with the ﬁrst principal component of pop-
ulation structure. Ancestry estimation has been described previously
(Coram et al. 2013). To assess the potential presence of multiple,
independent variants at the same locus inﬂuencing HDL-C trait, we
repeated regression analyses, conditioning on rs4804154. LD in locus
plots was calculated from WHI-imputed genotypes, and all chromo-
some coordinates correspond to hg19.
We constructed haplotypes based on ﬁve variants at ANGPTL8
that were previously reported as the GWAS index variants (rs4804154,
rs737337, and rs2278426) in studies of different ancestry groups
(Teslovich et al. 2010; Coram et al. 2013; Weissglas-Volkov et al. 2013;
Willer et al. 2013; Hanson et al. 2016) or are proxies (rs3745683 and
rs3760782) in high LD with both the European and African American
lead variants. We performed haplotype analyses using the “haplo.stat” R
package (Schaid et al. 2002), estimated haplotypes and haplotype fre-
quencies using the haplo.em function, and tested for association between
haplotypes and the concentration of phospholipids in medium HDL
(METSIM) or HDL-C (WHI) level using the haplo.glm function. We
assumed an additive model in which the regression coefﬁcient repre-
sented the expected change in inverse normalized HDL-C level with
each additional copy of the speciﬁc haplotype compared with the refer-
ence haplotype. The same covariates used for single variant analysis were
also used in the haplotype analysis model.
Expression quantitative trait association
RNAfromsubcutaneousadipose tissuewas extractedand theexpression
levels of probesets were measured using Affymetrix Human Genome
U219 Array in 770 METSIM participants (Civelek et al. 2016). The
expression quantitative trait locus (eQTL) for ANGPTL8 was not pre-
viously reported because of a gene name difference with RefSeq and
Ensembl. Expression data were normalized using Robust Multi-Array
Average (RMA) analysis (Irizarry et al. 2003). eQTL associations were
performed as previously described (Civelek et al. 2016). Brieﬂy, we
applied PEER analysis (Stegle et al. 2010) to account for complex non-
genetic factors in the RMA-normalized gene expression levels. We
adjusted for 35 inferred confounding factors and inverse normal trans-
formed the PEER-processed residuals. In eQTL analysis, we used ge-
notype dosages imputed using Haplotype Reference Consortium data
(McCarthy et al. 2016) to test for the variant association with expres-
sion levels of all genes within 1 Mb of rs737337. We assumed an
additive mode of inheritance and accounted for cryptic relatedness
between individuals using the EMMAX mixed model implemented
in EPACTS (Kang et al. 2010). Additionally, we performed conditional
analysis on the expression level of ANGPTL8 by adjusting for
rs4804155 and on the expression level of DOCK6 by adjusting for
rs17699089 to assess the presence of multiple, independent associa-
tions. We also performed conditional analysis using candidate func-
tional variant rs12463177 to assess the coincidence of GWAS and
eQTL signals. To examine the relationship between RMA-normalized
expression levels and HDL-C, we adjusted both traits for age and
BMI, inverse normal transformed the residuals, and then tested for
association in regression analyses.
MANTRA
To ﬁne-map the ANGPTL8 locus, we performed trans-ancestry meta-
analysis using MANTRA (Morris 2011). MANTRA accounts for the
shared similarity in closely related populations using Bayesian partition
model assuming the same underlying allelic effect. It models the effect
heterogeneity among distant populations by clustering according to the
shared ancestry and allelic effects. We conducted the analysis based on
the association summary statistics from GWAS in METSIM and WHI
and included variants present in both METSIM and WHI. We con-
structed a 99% credible set of variants by ranking all variants according
to their Bayes factors.
CAVIAR and PAINTOR
To prioritize functional variants, we analyzed variants at the ANGPTL8
locus using both CAVIAR (Hormozdiari et al. 2014) and PAINTOR
(Kichaev et al. 2014). CAVIAR estimates the posterior probability of a
variant being functional by jointly modeling the P-values and b asso-
ciation statistics, and PAINTOR leverages functional genomic annota-
tion data, in addition to association strength, to prioritize functional
variants. Bothmethods allow formultiple functional variants at the risk
locus. Using consistent alleles for METSIM and WHI African Ameri-
cans, we calculated Z scores based on P-values and the sign of b from
GWAS in these studies. For METSIM, the LD matrix was calculated
based on European data from the 1000 Genomes Project Phase 1. For
WHI African Americans, LD was calculated based on imputed data as
previously described (Reiner et al. 2012). In CAVIAR, we returned the
credible set that contains all of the true functional variants with 95%
conﬁdence level. The annotation matrix used in PAINTOR contained
data from the ENCODE project accessed from the UCSC Genome
Browser using the Table Browser tool. The matrix included HepG2
H3K4me1, H3K4me2, H3K4me3, and H3K27ac histone marks, DNase
hypersensitivity clusters (ENCODE v3) and transcription factor binding
(ENCODE v2) from the Broad Institute. Presence or absence of
overlap was determined by the UCSC Table Browser intersection
with the signal tracks. In PAINTOR, analysis was performed for
METSIM alone (Finns), WHI alone (African Americans), and the
two data sets together. We set the number of functional variants as 2,
3, 4, or 5 based on feasible running time. PAINTOR predicted var-
iants to be functional based on a posterior probability .0.1, a
threshold suggested previously (Kichaev et al. 2014).
Functional annotation
To identify regulatory overlap of HDL-C–associated variants with his-
tone marks, transcription factor binding, and DNase hypersensitivity
sites, we used data from the ENCODE and Roadmap Epigenome proj-
ects accessed through the UCSC genome browser (Bernstein et al. 2010;
Encode Project Consortium 2012). RNA-seq data were obtained from
the Roadmap Epigenome Project (Bernstein et al. 2010; adult liver and
adipose tissue) or a previous publication (Parker et al. 2013; HepG2).
We evaluated previously published positive correlations of DNase hy-
persensitivity sites with gene expression in liver cell types (Shefﬁeld
et al. 2013). LD calculations for selecting candidate variants were based
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on 1000 Genomes Phase 1 data. The AFR dataset was used for African
American LD and EUR for European LD.
Cell culture
HepG2, SW872, SGBS, 293T, 3T3L1, Huh-7, and MIN6 cell lines
were maintained at 37 with 5% CO2. HepG2 cells (ATCC, HB-8065)
were cultured in MEM-a (Gibco) supplemented with 10% FBS and
1 mM sodium pyruvate. SW872 cells (ATCC, HTB92) were cultured
in DMEM:F12 (Sigma) supplemented with 10% FBS. SGBS cells
(Wabitsch et al. 2001) were generously provided by Dr.MartinWabitsch
(University of Ulm) and cultured in DMEM:F12 (Sigma) supplemented
with 10% FBS and 5% 3.3 mM biotin/1.7 mM panthotenate solution.
SW872 and SGBS cells were transfected in the undifferentiated, preadi-
pocyte state. 293T cells (ATCC, CRL-3216) were cultured in DMEM
(Sigma) supplemented with 10% FBS and 200 mM L-glutamine. 3T3-
L1 cells (ATCC, CL-173) were cultured and differentiated as described in
the ATCC protocol. Huh-7 cells (JCRB0403, Japanese Collection of Re-
search Bioresources Cell Bank, National Institute of Biomedical Innova-
tion), were cultured in DMEMwith high glucose (Gibco) with 10% FBS,
1 mM sodium pyruvate, 1 mM nonessential amino acids (Sigma), and
1 mM L-glutamine. MIN6 cells (Miyazaki et al. 1990) were cultured in
DMEM (Sigma), supplemented with 10% FBS, 1 mM sodium pyruvate,
and 0.1 mM b-mercaptoethanol.
Dual luciferase transcriptional reporter assays
We PCR-ampliﬁed fragments surrounding each regulatory region or
variant with ﬁve PRIME Mastermix (ﬁve PRIME) or Phusion High-
Fidelity Polymerase (New England Biosystems) with the primers listed
in Supplemental Material, Table S1 in File S1 from DNA of individuals
homozygous for alleles associated with increased or decreased HDL-C.
Gateway attB sites were included in primers and Gateway cloning was
used to insert fragments into a Gateway-compatible pGL4.23 (minimal
promoter) or pGL4.10 (promoterless) ﬁreﬂy luciferase reporter vector
(Promega). Fragments containing HDL-C–associated variants are des-
ignated as forward or reverse based on their orientation with respect to
the genome and the ANGPTL8 gene. The 5-kb and promoter regions
were only cloned in the forward orientation (pGL4.10) because they
include the ANGPTL8 promoter. Regions were isolated based on epi-
genetic marks of promoter and/or enhancer regions surrounding the
HDL-C–associated variants. We isolated three to ﬁve independent
clones (biological replicates) for each allele for each orientation and
veriﬁed by sequencing. Each clone was cotransfected with Renilla lu-
ciferase vector in duplicate (HepG2, 293T, Huh-7, SW872) or triplicate
(SGBS, 3T3L1) wells (technical replicates) using FUGENE 6 (HepG2,
293T, Huh-7, SW872, 3T3L1; Promega), Lipofectamine 2000 (Min6;
Life Technologies), or Lipofectamine 3000 (SGBS; Life Technologies).
Twenty-four (SGBS) or 48 h (all other cell types) after transfection, we
collected cell lysates and assayed for luciferase activity using the Dual-
Luciferase Reporter Assay System (Promega). Fireﬂy luciferase activity
of the clones containing the PCR fragments was normalized to Renilla
luciferase readings to control for differences in transfection efﬁciency.
We repeated all luciferase transcriptional reporter experiments on in-
dependent days and obtained consistent results. Data are reported as
fold change in activity relative to an empty pGL4.23 or pGL4.10 vector.
We used two-sided Student’s t-tests to compare luciferase activity be-
tween alleles or haplotypes.
Electrophoretic mobility shift assays
For electrophoretic mobility shift assays (EMSAs), we prepared nuclear
cell extracts fromHepG2,HuH-7, SGBS, 3T3L1,SW872, andMIN6cells
using the NE-PER nuclear and cytoplasmic extraction kit (Thermo
Scientiﬁc). Protein concentration was measured with a BCA assay
(Thermo Scientiﬁc), and lysates were stored at 280 until use. We
designed 17–19 bp biotin– or IR-Dye 700–labeled oligos around the
HDL-C–associated variants (Table S1 in File S1) for both alleles. We
annealed double-stranded oligos and performed binding reactions as
previously described (Kulzer et al. 2014). We used 4–6 mg of antibody
in supershift assays and 100–200 ng CEBPB-puriﬁed protein for select
EMSAs. Binding reactions were run on nondenaturing PAGE DNA
retardation gels in 0.5· TBE (Lonza). For biotin-labeled oligos, we
transferred the reactions to Biodyne nylon membranes (Thermo
Scientiﬁc), cross-linked them on a UV cross-linker (Stratagene),
and detected DNA–protein complexes by chemiluminescence. For
IR-DYE 700–labeled oligos, we imaged gels on a LiCor Odyssey CLx
Imaging System.We repeated all EMSA experiments on another day
with consistent results.
Data availability
Plasmids are available upon request. Supplemental ﬁgures and tables
contain all relevant data.
RESULTS
Regulation of tissue-selective expression of ANGPTL8
ANGPTL8 expression is largely restricted to liver and adipose tissues
(Quagliarini et al. 2012; GTEx Consortium 2013). To determine drivers
of ANGPTL8 tissue speciﬁcity, we tested candidate regulatory regions
in human hepatocyte (HepG2, Huh-7), human preadipocyte (SGBS),
human adipocyte (SW872), mouse adipocyte (3T3-L1), human em-
bryonic kidney (293T), and mouse islet b (MIN6) cell lines. We
tested a region extending 400 bp upstream of the transcription start
site that spans epigenetic marks characteristic of promoters, and a
regulatory region that extends 5 kb upstream of the transcription
start site (regions shown in Figure 1). The 400 bp promoter contains
no HDL-C–associated variants; the 5-kb region contains sevenHDL-
C–associated variants (rs200788077, rs56322906, rs6511729, rs3760782,
rs737337, rs737338, and rs3745683). We tested these candidate regions
in transcriptional reporter luciferase assays. In comparison to empty
vector, the promoter increased transcriptional activity ﬁvefold in HepG2
(P, 0.0001) and 1.6-fold in Huh-7 (P = 0.04), but not in any other cell
type (P . 0.5, Figure 2A). The 5-kb region increased transcriptional
activity in HepG2 by eightfold in HepG2 (P = 0.0007) and sixfold in
Huh-7 (P = 0.002) compared with empty vector and increased transcrip-
tional activity twofold in preadipocyte (SW872, P = 0.0007) and adipo-
cyte (3T3-L1, P = 0.023) cells compared with empty vector (Figure 2B).
Neither region showed transcriptional activity in MIN6 or 293T cells.
These data suggest that the 400-bp region contains promoter regulatory
elements contributing to tissue speciﬁcity in liver, but may be mediated
by additional enhancer elements, especially in adipocytes.
Characterization of the ANGPTL8 HDL-C GWAS locus
To characterize and determine shared variants of the ANGPTL8 asso-
ciation signal across populations, we analyzed the METSIM study of
Finns (N = 8380) and the African Americans subset (N = 8244) from
the WHI (Coram et al. 2013). In a preliminary METSIM analysis, the
variants most strongly associated with HDL-C at the ANGPTL8 locus
were rs737337 (P = 7.7 · 1024, b = 20.09) and its LD proxies; these
variants were more strongly associated with the concentration of phos-
pholipids in medium HDL particles (P = 1.9 · 1027, b =20.14; Figure
3A and Table S2 in File S1) than HDL-C (P = 7.7 · 1024, b = 20.14)
(Davis J.P., Huyghe J.R., Jackson A.U., Stringham H.M., Teslovich,
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T.M., Welch R.P., Fuchsberger C., Locke A.E., Narisu N., Chines P.S.,
Kangas A.J., Soininen P., Ala-Korpela M., Kuusisto J., Collins F.S.,
Laakso M., Mohlke K.L., Boehnke M., unpublished data). Association
analyses conditioned on rs737337 showed no evidence for any addi-
tional signals (all P. 8.0 · 1024, Figure S1B and Table S2 in File S1). In
WHI, the lead variant associated with HDL-C is rs4804154 (P = 8.4 ·
10217), located 13 kb from rs737337, and we did not observe evidence
of any additional signals (P . 4.8 · 1024, Figure 3B, Figure S1D, and
Table S3 in File S1). rs4804154 is in low LD with the reported African
American lead variant rs12979813 (r2 = 0.18 AFR). rs12979813 is the
most strongly associated genotyped variant in the previously reported
African American sample (Coram et al. 2013), which includes theWHI
study, but rs4804154 is the strongest variant after imputation in WHI.
These two lead variants, rs737337 and rs4804154, are in moderate
pairwise LD in Europeans (r2 = 0.67 EUR) and in low pairwise LD in
Africans (r2 = 0.26 AFR). rs737337 was among the most strongly
associated variants in WHI (P = 9.1 · 10210) and the same was true
of rs4804154 in METSIM (P = 5.7 · 1025). The rare coding variant
rs145464906 in ANGPTL8 (Peloso et al. 2014) is not present in
METSIM and was not signiﬁcantly associated with HDL-C in WHI
(P = 0.30). Conditioning on the common coding variant rs2278426 atten-
uates, but does not abolish, the signal in both populations (METSIM
rs737337, P = 0.03; WHI rs4804154, P = 1.82 · 1024). Conditioning on
the lead variant abolished the association with rs2278426 (WHI, P =
0.78; METSIM, P = 0.86), suggesting that the regulatory variants cap-
turemore of the association signal than rs2278426 alone. Becausemany
GWAS loci are shared across populations, the presence of an associa-
tion signal in both WHI and METSIM supports the hypothesis of at
least one shared functional variant across populations.
To further characterize the locus across populations, we conducted
haplotype association analyses in METSIM and WHI (Table 1). By
comparing variants across haplotypes and populations, we can hypoth-
esize which variants represent the inheritance pattern of variants that
have a functional effect. We included ﬁve variants in the analyses: the
lead variants from European (rs737337), African American (rs4804154),
Mexican/Pima Indian (rs2278426), and East Asian (rs3760782) studies
and the one variant (rs3745683) in high LD (r2. 0.8) with the leads in all
four studies. The most common haplotype in both METSIM and WHI
contained alleles individually associated with increased HDL-C (haplo-
type 1, Table 1). In both studies, the haplotype containing all the alleles
individually associated with decreased HDL-C (haplotype 3) showed the
strongest association with HDL-C (^b =20.044, P, 1.0 · 10222 inWHI
and^b =20.146,P=5.3· 1027 inMETSIM).Haplotypes 1 and 2 differed
only for rs737337 alleles. Haplotype 2 is common in African Americans
(21% frequency) and nearly absent in Finns (0.02% frequency), which
explains the different extent of r2-based LD in these populations. The
Figure 1 Thirteen variants overlap predicted regulatory regions. Thirteen variants overlap regulatory regions deﬁned by histone marks, chromatin
accessibility, and transcription factor binding. The full set of 42 candidate variants span a 39-kb region (Figure S4 in File S1). Green rectangles denote
DNase hypersensitivity peaks correlated with ANGPTL8 expression across 112 cell lines in a previous study (Shefﬁeld et al. 2013). DNase hyper-
sensitivity correlation with DOCK6 expression is not indicated because the correlated peaks do not overlap HepG2 or hepatocyte DNase peaks. Gray
rectangles represent transcription factor binding; the identities of transcription factors are listed in Table S5 in File S1. Data were accessed from
ENCODE, the Epigenome Roadmap Atlas, and the UCSC Genome Browser. ENCODE ChromHMM: gray, heterochromatin; blue, insulator; green,
transcription; yellow and orange, enhancer; red and pink, promoter. Roadmap ChromHMM: orange, enhancer; light green, genic enhancer; dark
green, transcription; blue, heterochromatin; red, promoter. Black rectangles represent regions analyzed in transcriptional reporter assays.
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small effect sizes of haplotype 2 (^b= 20.01 in WHI), 3 (^b = 20.044 in
WHI,^b =20.146 inMETSIM), and 5 (^b =20.009 inWHI,^b =20.049
in METSIM) suggest that rs737337, rs2278426, and rs4804154 may con-
tribute to, but are not alone responsible for, the association signal. These
data are consistent with a signal shared across populations driven by one
or more functional variants represented by rs3745683 and rs3760782,
with potential additional contributions from rs737337, rs2278426, and/or
other proxies.
eQTL associations with HDL-C–associated variants and
nearby genes
To determine which gene(s) the HDL-C–associated variants may affect,
we investigated eQTL associations. We observed an eQTL association in
subcutaneous adipose tissue from 770 METSIM study participants for
both ANGPTL8 (rs4804154, P = 1.0 · 1029; Figure 3C, Figure S2 in File
S1, and Table 2) and DOCK6 (rs17699089, P = 7.2 · 1027; Figure S2 in
File S1, Table 2, and Table S4 in File S1), but not any other gene within
1Mb of rs737337 (Table S4 in File S1). TheMETSIM andWHIHDL-C–
associated variants were among the variantsmost strongly associatedwith
bothANGPTL8 andDOCK6mRNA levels (Figure 3 and Table S4 in File
S1), suggesting that the same variants associated with HDL-Cmay act by
affecting expression level ofANGPTL8 and/orDOCK6. Conditional anal-
yses were performed to conﬁrm the coincidence of the GWAS and eQTL
signals. For both genes, alleles associated with lower HDL-C levels were
associated with lower mRNA levels. In addition, ANGPTL8mRNA level
was associated with HDL-C level in METSIM samples (P = 0.017, Figure
S3 in File S1), whereas DOCK6 was not (P = 0.42, Figure S3 in File S1).
Evidence that the variants most strongly associated with HDL-C are also
most strongly associated with ANGPTL8 mRNA levels suggests that a
regulatory mechanism acts at this GWAS locus.
Selection of variants to test for allelic differences in
regulatory activity
Prioritizing variants at GWAS loci for functional study can be chal-
lenging, especially at loci with regulatory mechanisms. To narrow
Figure 2 Cell-type speciﬁcity of ANGPTL8 is inﬂuenced by nearby
regulatory regions. Candidate regulatory regions were tested in a
pGL4.10 vector in six cell types to determine drivers of tissue speci-
ﬁcity. Reporter activity was normalized to empty vector (EV) in each cell
type. Data are represented as the mean 6 SD of 10 biological repli-
cates. (A) A 400-bp promoter. (B) A 5-kb regulatory region including
the promoter. Comparison of the 400-bp promoter vs. 5-kb regulatory
region; P , 0.05 for cell types. Cell lines: HepG2, human hepatocel-
lular carcinoma (liver); Huh-7, human hepatocellular carcinoma; SGBS,
human preadipocyte; SW872, human adipocyte; 3T3L1, mouse adipo-
cyte; MIN6, mouse pancreatic b cell; 293T, human embryonic kidney.
Figure 3 Locus plots of HDL-C and eQTL associations near ANGPTL8.
(A) Concentration of phospholipids in medium HDL in the METSIM
study of Finnish individuals (N = 8380). Variants are colored according
to LD (r2) with rs737337 (purple), the lead variant in European meta-
analyses by GLGC. (B) HDL-C association in the WHI subset of African
American individuals (N = 8244). Variants are colored according to LD (r2)
with rs4804154 (purple). (C) HDL-C–associated variants are also asso-
ciated with ANGPTL8 expression in 770 subcutaneous adipose samples
from the METSIM study. The European and African American lead var-
iants (rs737337 and rs4804154, labeled in plots) are among the most
signiﬁcant variants. Variants are colored according to LD (r2) with
rs4804154 (purple).
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variants that may have regulatory function, we considered three meth-
ods: LDwith the leadGWASvariants, three ﬁne-mapping algorithms in
each of METSIM and WHI, and overlap with predicted regulatory
regions (Figure S4 in File S1). First, we considered variants in LD with
the lead GWAS variants in European and/or African American ances-
try individuals (1000 Genomes EUR and AFR). Because the variants in
Europeans are of moderate allele frequency (MAF 0.07), we consid-
ered variants that meet an LD threshold r2 . 0.5. In total, 42 variants
exhibited r2. 0.5 with a lead HDL-C–associated variant in at least one
study and could be considered as candidates for regulatory function
(Figure S5 and Table S5 in File S1). As a second approach to prioritize
candidate variants at this locus, we used the MANTRA, CAVIAR, and
PAINTOR algorithms to interpret the HDL-C–associated variants in
the METSIM Finnish and WHI African American ancestry groups
(Table S6, Table S7, and Table S8 in File S1). Finally, we identiﬁed
candidate variants based on simple positional overlap with evidence
of predicted regulatory regions, as variants overlapping these regions
are more likely to be functional (Figure S5 and Table S5 in File S1)
(Bernstein et al. 2010; Encode Project Consortium 2012; Parker et al.
2013; Shefﬁeld et al. 2013). Nine variants identiﬁed in at least one ﬁne-
mapping analysis overlapped regulatory regions (rs12463177, rs17766692,
rs17699089, rs200788077, rs56322906, rs3760782, rs737337, rs737338,
and rs3745683). We considered these nine variants to represent the most
plausible candidate variants based both on ﬁne-mapping and regulatory
overlap and examined them for allelic differences on regulatory function.
To compare the set of ninemost plausible candidate variants to those that
only show regulatory overlap, we also examined four additional variants
in regulatory regions that were not identiﬁed by any ﬁne-mapping anal-
ysis (rs34692794, rs10421795, rs10421382, and rs6511729). Thus,
we examined a total of 13 variants in assays examining allelic effects
on regulatory function. All 13 variants are located within 9 kb of the
ANGPTL8 transcription start site (Figure 1 and Table S5 in File S1).
Functional characterization of candidate variants
We examined the candidate variants for allelic differences in assays of
regulatory function in human liver-derived (HepG2, Huh-7), preadi-
pocyte (SGBS), and adipocyte (SW872) cells. We chose these cell types
because ANGPTL8 is expressed in liver and adipose, they had the high-
est transcriptional activity in our cell type-speciﬁcity assays, and they
have roles in HDL-C metabolism. We tested variants individually or as
a haplotype in luciferase transcriptional reporter assays and/or in
EMSA (Figure S6 and Figure S7 in File S1). Among the variants ana-
lyzed, rs12463177, which was identiﬁed in all three ﬁne-mapping anal-
yses and is a candidate at r2 . 0.5 in both populations (r2 = 0.74 with
rs737337 EUR, r2 = 0.93 with rs4804154 AFR), and is 8 kb upstream
from the ANGPLT8 transcription start site showed signiﬁcant (P ,
0.05) allelic differences in two assays of regulatory function (Figure 4).
In luciferase transcriptional reporter assays in HepG2, a 697-bp region
containing rs12463177-G showed 1.2 to 1.4-fold increased enhancer
activity (P = 0.02 forward orientation;P= 0.004 reverse) comparedwith
rs12463177-C. While modest, this allelic difference was replicated in
three independent experiments. The signiﬁcant effect on transcrip-
tional activity was not replicated in Huh-7, SGBS, and SW872 cells,
in which this region showed repressor activity; however, the trend be-
tween the alleles is consistent with HepG2, at least in the reverse ori-
entation (Figure S6 in File S1). In EMSAs using HepG2 and SGBS
nuclear extract, the rs12463177-G allele showed increased binding (Fig-
ure 4, and Figure S7 and Figure S8 in File S1). The direction of effect of
rs12463177 transcriptional activity is consistent with the eQTL direc-
tion. A functional role for rs12463177 is consistent with additional
evidence that rs12463177 overlaps a DNase hypersensitivity site thatn
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was previously correlated toANGPTL8 expression (Shefﬁeld et al. 2013;
green rectangle in Figure 1) and that the eQTL association signal is
attenuated when conditioned on rs12463177 (Figure S2 in File S1 and
Table 2).
Six additional variants (rs17699089, rs200788077, rs56322906,
rs3760782, rs737337, and rs3745683) showed evidence of allelic differ-
ences in an assay for regulatory function and two (rs17766692 and
rs737338) did not (Figure S6, Figure S7, Figure S8, and Figure S9 in File
S1). rs56322906 was only tested in transcriptional reporter assays as
part of the 5-kb haplotype described below (Figure S11 in File S1).
rs737337 showed by far the strongest enhancer activity in transcrip-
tional reporter assays, an up to 60-fold increase compared with empty
vector in HepG2 (Figure S6 in File S1), and rs737337-C shows
strong allele-speciﬁc binding in liver cell types (Figure S7 in File
S1). Supershift experiments using HepG2 nuclear extract identiﬁed
RXRa as binding to this probe, although not as part of the allele-
speciﬁc complex (Figure S10 in File S1). Interestingly, the four var-
iants that overlap regulatory regions but were not predicted by
any ﬁne-mapping analysis (rs34692794, rs10421795, rs10421382, and
rs6511729) did not show allelic differences in protein binding (Figure S9
in File S1). In total, we observed evidence of functional activity for seven
of the nine candidate regulatory variants in these assays (Figure 5).
To examine the effect on transcriptional activity of multiple variants
together with the ANGPTL8 promoter, we tested 5-kb haplotypes located
immediately upstream of the ANGPTL8 transcription start site. This re-
gion includes ﬁve of the seven variants showing allelic differences in pro-
tein binding and/or transcriptional activity when examined separately
(rs200788077, rs56322906, rs3760782, rs737337, and rs3745683; Figure
S6 in File S1) and two variants that did not show evidence of allelic
differences (rs6511729 and rs737338; Figure S9 in File S1). Transcriptional
reporter assays of the smaller segments containing individual variants had
shown both activator (e.g., rs737337) and repressor (e.g., rs3760782 and
rs3745683) activity. The 5-kb haplotype acted as an enhancer in HepG2,
Huh-7, SGBS, and SW872, with intermediate activity observed between
the individual segments, but did not show signiﬁcant differences in tran-
scriptional activity between the two haplotypes (Figure S11 in File S1).
These results suggest a complex regulatory mechanism involving en-
hancer and repressor regions that work in concert to regulate expression.
DISCUSSION
In this study, we examined the tissue speciﬁcity of ANGPTL8, reported
the ﬁrst eQTL for variants at the ANGPTL8 HDL-C GWAS locus in
adipose tissue, and identiﬁed variants at the GWAS locus that exhibit
allelic differences in assays of regulatory function. We found that a
400-bp promoter is the main driver of tissue speciﬁcity in liver, and
that expression may be mediated by additional enhancer elements
within 5 kb upstream of ANGPTL8, especially in adipocytes. Of
seven candidate regulatory variants that showed allelic differences
in transcriptional activity and/or protein binding, rs12463177
showed the clearest allelic differences consistent with the direction
of theANGPTL8 eQTL. These data suggest that multiple regions and
potentially multiple variants regulate ANGPTL8 expression in liver
and adipose tissue.
ANGPTL8 is a strong candidate gene at this GWAS locus. Al-
though we observed coincidental association between the GWAS
variants and transcript level for both ANGPTL8 and DOCK6 in
subcutaneous adipose tissue samples, ANGPTL8 mRNA level was
associated with HDL-C in METSIM, whereas DOCK6 mRNA level
was not (Figure S3 in File S1). DNase hypersensitivity sites that
overlap regulatory variants are correlated to ANGPTL8 expression
(Figure 1), providing further support for ANGPTL8 as the target
gene. ANGPTL8 protein levels have been shown to be inversely
n Table 2 Associations with ANGPTL8 and DOCK6 expression in subcutaneous adipose tissue
Variant Allelesa Gene Effectb SE P-Value Pcond-eSNP Pcond-rs12463177
r2 with
eSNP (EUR)c
r2 with
eSNP (AFR)c
rs4804155 G/C ANGPTL8 20.499 0.081 1.04 · 1029 — 0.516 — —
rs737337 C/T ANGPTL8 20.526 0.098 9.74 · 1028 0.244 0.402 0.67 0.40
rs4804154 T/C ANGPTL8 20.500 0.081 1.38 · 1029 0.762 0.270 1.00 0.48
rs12463177 C/G ANGPTL8 20.479 0.080 3.84 · 1029 0.570 — 0.94 0.47
rs17699089 G/A DOCK6 20.406 0.081 7.21 · 1027 — 0.005 — —
rs737337 C/T DOCK6 20.298 0.099 2.68 · 1023 0.324 0.413 0.74 0.29
rs4804154 T/C DOCK6 20.398 0.082 1.65 · 1026 0.253 0.267 0.94 0.91
rs12463177 C/G DOCK6 20.382 0.081 3.06 · 1026 0.029 — 1.00 0.98
Lead eQTL variants for ANGPTL8 (rs4804155) and DOCK6 (rs17699089), lead GWAS variants (rs4804154 and rs737337), and functional candidate variant rs12463177
association with ANGPTL8 and DOCK6 expression in 770 primary subcutaneous adipose samples. Conditional analysis on each lead eSNP and the candidate
functional variant rs12463177 attenuated both the ANGPTL8 and DOCK6 association signals. Pcond, conditional P-value; eSNP, strongest associated eQTL variant.a
The HDL-C–decreasing and eQTL effect alleles are presented ﬁrst.
b
Effect size is shown as the inverse normal transformed expression levels [log2(ﬂuorescence intensity)] with each additional copy of the allele.c
r2 is calculated from 1000 Genomes Phase 1 data.
Figure 4 Allelic differences in regulatory assays of rs12463177 (A) A
698-bp region containing either allele of rs12463177 was cloned
into the pGL4.23 vector and transfected in HepG2 cells. Data are
represented as the mean 6 SD of 3–5 biological replicates. Luciferase
activity was normalized to empty vector (EV) and P-values were de-
termined by t-tests.  P , 0.05,  P , 0.01. (B) Differential protein
binding was evaluated in vitro using EMSA. IR-labeled probes contain-
ing either allele of rs12463177 were incubated with 10 mg HepG2
nuclear protein. The arrow shows stronger binding for rs12463177-G.
Consistent binding was observed with SGBS nuclear protein (Figure S7
in File S1). HDL-C–increasing alleles are presented ﬁrst.
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associated with HDL-C (Yi et al. 2015). This direction is opposite of
the association we observed with ANGPTL8 expression and HDL-C;
however, others have suggested that ELISA methods may not con-
sistently quantify serum ANGPTL8 levels (Fu et al. 2014a). Further-
more, ANGPTL8 inhibits lipoprotein lipase when coexpressed with
ANGPTL3, giving a direct connection to lipid metabolism (Haller
et al. 2017). While we cannot rule out a role for DOCK6, these lines
of evidence and a rare coding variant in ANGPTL8 associated with
HDL-C (Peloso et al. 2014) suggest ANGPTL8 as the most likely
target gene at this HDL-C GWAS locus.
The ANGPTL8 HDL-C GWAS locus exhibited unusual character-
istics in ﬁne-mapping because the associated variants deﬁned by LD r2
with the lead GWAS variants span a larger chromosomal region in
African Americans than in Europeans, opposite of most loci in the
genome (International HapMap Consortium 2003). Our haplotype
association analyses showed that the LD differences are due to a hap-
lotype with 20% frequency in African Americans from WHI that is
essentially not observed in Finns fromMETSIM (0.02% frequency). At
this locus, low-frequency haplotypes (frequency , 0.03; Table 1) dis-
tinguish r2 thresholds of 0.8 and 0.5 in Finns, and the r2 dependence on
allele frequency suggests that a LD threshold of r2 . 0.8 for selecting
candidate variants may be too restrictive and miss potentially func-
tional variants. Here, we considered an initial set of candidate variants
based on a more liberal threshold of r2 . 0.5, resulting in 42 total
variants. We then tested nine variants predicted by MANTRA, CAV-
IAR, and PAINTOR and that overlapped regulatory datasets in
functional assays. Seven of nine variants showed evidence of allelic
differences (Figure 5), but only rs12463177 and rs17699089 showed
differences consistent with the direction of the eQTL association. Of
four additional variants that overlapped regulatory regions but were not
predicted to be functional in ﬁne-mapping assays, none showed evi-
dence of regulatory activity. Taken together, these data suggest that the
joint use of ﬁne-mapping and regulatory overlap can successfully iden-
tify variants exhibiting allelic differences in functional assays.
Themechanismsbywhichthevariants that showedallelicdifferences
in functional assaysmay work in concert remains unclear. The effect on
transcriptional activityof rs12463177wasmodest andonly signiﬁcant in
one cell type (Figure 4 and Figure S6 in File S1). This marginal effect
observed in cell lines may not represent the physiological effect in vivo.
The magnitude of effect of rs737337 was much greater (50-fold in-
creased transcriptional activity), but did not show signiﬁcant allelic
differences, in contrast to a previous report (Schmidt et al. 2015).
rs737337 exhibited strong liver-speciﬁc, allele-speciﬁc protein binding,
but the speciﬁc transcription factor(s) remain unknown. One possible
mechanism is that the regulatory region containing rs737337 is a strong
enhancer that drives expression of ANGPTL8, but that the region con-
taining rs12463177 is important for regulating allele-speciﬁc expres-
sion. Transcriptional regulators bound at the multiple variants may act
together via chromosomal looping with the ANGPTL8 promoter. Fur-
ther experiments, especially in vivo, are needed to elucidate the precise
roles and interactions of the seven variants that showed allelic differ-
ences in transcriptional activity and/or protein binding.
In this study, we identiﬁed ANGPTL8 as the target gene at this
HDL-C GWAS locus, determined regulatory drivers of tissue spec-
iﬁcity, and combined ﬁne-mapping approaches and regulatory over-
lap with experimental assays to identify variants that may contribute
to the HDL-C GWAS signal at ANGPTL8. Identifying variants
underlying GWAS loci contributes to a growing understanding of
target genes, their direction of effect, andmetabolic phenotypes. Our
results are consistent with previously described results at other
GWAS loci where multiple common regulatory variants act together
(Corradin et al. 2014; He et al. 2015; Roman et al. 2015), and con-
tinued work on the ANGPTL8 locus will further clarify the complex
mechanism of these variants.
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